The Glucose Never Lies® Podcast

Suggest guests or get in contact
Three months ago, GNL was a website full of excellent content that was genuinely hard to find. In Episode 38, John Pemberton and Creative Director Anjanee Kohli talk through what happened next: a complete website rebuild, five interactive explorers, the launch of GNL Grace, real-world validation on 1.5 million patient days, and what the Robin Hood model of type 1 diabetes education actually means.
In this episode:
CGM guide update and the five-out-of-five accuracy chart
How the five GNL Explorers work and how clinicians are using them in practice
GNL Grace: a bounded AI educational advisor built on 2,000 curated citations
Three Grace tiers: Basic (free), Pro (30 queries/month for subscribers), Max (manuscript-grade output)
The Robin Hood model: industry grants fund free education for everyone
Real-world validation: 33 assessments on 1.5 million patient days
Why the skill of the future in healthcare is compassion, not knowledge
Phil Hayes joining as Technical Director
GNL merch and the Diabetes UK giveaway
Chapters:
00:00 Introduction
01:55 GNL Grace announcement
02:32 CGM guide and accuracy chart
05:30 Phil Hayes and the explorer infrastructure
09:40 GNL Grace: the six-layer bounded AI
10:50 Grace tiers and the Robin Hood model
13:31 Grace Max: manuscript-grade output
17:31 Real-world validation on 1.5 million patient days
19:58 The skill of the future is compassion
30:09 What went wrong and lessons learned
35:06 GNL merch
36:10 Closing
Links:
Show notes: theglucoseneverlies.com/episode-38-quarterly-review
GNL Grace: theglucoseneverlies.com/gnl-grace
GNL Explorers: theglucoseneverlies.com/gnl-explorers
CGM Series hub: theglucoseneverlies.com/10-13-cgm-series
Host: John Pemberton. Director of Creativity: Anjanee Kohli.
This content is for educational exploration only. It is not medical
Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.
The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2
Enquiries
Collaboration: John Pemberton — [email protected]
Creatives: Anjanee Kohli — [email protected]
Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
X: https://twitter.com/GlucoseNLies
Disclaimer
This content is for informational purposes only and does not constitute medical advice.
© The Glucose Never Lies Ltd. All rights reserved.

Suggest guests or get in contact
Most people with T1D have switched their CGM high alert off. Not because they do not care - because it goes off every time they eat and there is nothing they can do about it. Episode 37 is about what Dexcom built to fix that.
Adam Dawes, Senior Medical Affairs Manager at Dexcom UK and Ireland - and a former paediatric diabetes nurse specialist - joins John Pemberton for the third manufacturer episode of the CGM Series. An honest clinical conversation about the Dexcom G7 and ONE+, what separates them, and where Dexcom is heading next.
This episode covers:
- Dexcom G7 vs Dexcom ONE+: same hardware platform, different software, and what that means for matching the right sensor to the right patient
- Delay 1st Alert: why it is one of the most underused alerts in CGM, how it eliminates alarm fatigue without reducing safety, and how John uses it himself
- AID integrations: Tandem T:slim X2, Omnipod 5, mylife, and the Tandem Mobi
- CGM for type 2 diabetes: the biofeedback argument and why immediate glucose feedback changes behaviour in ways a quarterly HbA1c never can
- The Dexcom roadmap from ATTD 2026: 15-day sensor, Dexcom G8 next generation sensor, EPIC integration, Clarity updates, and generative AI
- Why insulin dosing will never be a commodity market - and what people with T1D need to understand as new CGMs enter the UK
- The FDA manufacturing findings: what happened, how Dexcom responded, and why the new Ireland factory matters
Show notes: https://theglucoseneverlies.com/episode-37-dexcom-g7-one-plus/ | CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/
Have more questions about CGM, the Dexcom G7 or ONE+? Ask GNL Grace: https://theglucoseneverlies.com/gnl-grace/
Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00
The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.
Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.
The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2
Enquiries
Collaboration: John Pemberton — [email protected]
Creatives: Anjanee Kohli — [email protected]
Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
X: https://twitter.com/GlucoseNLies
Disclaimer
This content is for informational purposes only and does not constitute medical advice.
© The Glucose Never Lies Ltd. All rights reserved.

Suggest guests or get in contact
CGM Series | The Glucose Never Lies® Podcast
Three of the UK's leading diabetes specialist nurses on why CE marking is not a quality standard for CGM accuracy, why data sufficiency must come before device comparison, and what ATTD 2025 revealed about where diabetes technology is heading. A frank, clinical conversation grounded in years of front-line practice — and the story of how the DSN Forum's five-point accuracy scoring system was built.
In this episode:
Why the DSN Forum created its CGM comparison chart and how it has evolved
Why CE marking is not a quality standard for CGM accuracy
How the five-point accuracy scoring system works and what it requires from a device
Why only four devices currently meet the data sufficiency standard
What 20/20 and 40/40 agreement rates mean in real clinical terms
Why everyone using CGM for insulin decisions still needs a working finger-prick meter
The calibration debate: does the option to calibrate add safety or risk?
What ATTD 2025 revealed about fully closed loop systems — and who may not benefit
The case for GLP-1 in type 1 diabetes and why priority access matters
Abbott's continuous ketone monitor: opportunity, unknowns, and risks
AID system optimisation, insulin on board, and the GNL AID System Explorer
Chapters:
00:00 — Introduction: meeting Amanda, Beth and Tamsin
02:14 — Why the DSN Forum CGM comparison chart was created
06:47 — Turning complex CGM evidence into a practical scoring system
16:23 — How CGM choice works in real clinical settings
20:36 — Why finger-prick testing still matters — and the calibration debate
29:26 — What stood out at ATTD 2025
44:03 — AID systems, insulin on board, and the GNL AID optimiser
49:49 — Where to find the DSN Forum, the chart, and closing thoughts
Guests: Amanda Williams (Lead Diabetes Nurse, East Kent), Beth Kelly (Clinical Lead DSN, Wiltshire), Tamsin Fletcher-Salt (Lead DSN, University Hospital North Midlands). All core members of the Diabetes Specialist Nurse Forum UK.
Links:
Full show notes: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/
DSN Forum CGM Comparison Chart: https://www.diabetesspecialistn
Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.
The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2
Enquiries
Collaboration: John Pemberton — [email protected]
Creatives: Anjanee Kohli — [email protected]
Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
X: https://twitter.com/GlucoseNLies
Disclaimer
This content is for informational purposes only and does not constitute medical advice.
© The Glucose Never Lies Ltd. All rights reserved.

Suggest guests or get in contact
CGM Series | The Glucose Never Lies® Podcast
CGM accuracy is usually described with a single number: MARD. But a low MARD can hide significant risk if the study behind it was poorly designed. Professor Othmar Moser — one of the leading independent CGM accuracy researchers — explains what study design actually determines, why meal and insulin challenges are non-negotiable, and what people with type 1 diabetes and clinicians should look for when evaluating any accuracy claim.
In this episode:
What MARD is and why it misleads when used in isolation
The five study design questions that determine what accuracy data actually means
Why 20/20 and 40/40 agreement rates reveal what MARD cannot
Why meal and insulin challenges are essential for real-world accuracy testing
What CE marking does and does not guarantee about CGM performance
Why peer-reviewed, independent evidence is the gold standard — and how little of what is cited meets it
How study design quality shapes what we actually know about CGM risk
Professor Moser's perspective as a researcher who designs and runs these studies
Guest: Professor Othmar Moser, Medical University of Graz, Austria. Leading figure in independent CGM accuracy study design and insulin-related exercise physiology research in type 1 diabetes.
Links:
Full show notes: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/
CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/
CGM Guide Part 1 — How to Choose a CGM: https://theglucoseneverlies.com/select-continuous-glucose-monitor-cgm-understanding/
Episode 36 — DSN Forum: CGM Accuracy and ATTD 2025: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/
Watch on YouTube: https://youtu.be/zTdTps42kQ8
Educational purposes only. Not medical advice. Always work with your diabetes care team.
Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00
The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.
Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.
The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2
Enquiries
Collaboration: John Pemberton — [email protected]
Creatives: Anjanee Kohli — [email protected]
Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
X: https://twitter.com/GlucoseNLies
Disclaimer
This content is for informational purposes only and does not constitute medical advice.
© The Glucose Never Lies Ltd. All rights reserved.

Suggest guests or get in contact
How do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?
In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.
Full show notes:
https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/

KEY TOPICS
• How Sweden’s national diabetes registry drives accountability and rapid improvement
 • Why structured onboarding and early follow-up are essential for CGM and AID success
 • The role of national collaboration between clinics to share best practice
 • Why the highest HbA1c group should often be first in line for AID systems
 • Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target
• Equity in diabetes technology: checking subconscious bias with real data
• Why celebrating small improvements builds long-term engagement
WHAT YOU’LL LEARN
✓ Why early investment in education and follow-up changes long-term outcomes
 ✓ How national benchmarking between clinics improves diabetes care
 ✓ Why targets matter — changing what you measure changes what improves
 ✓ How to use AID systems strategically for people struggling with bolusing
 ✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes
 ✓ The importance of psychology, social support, and multidisciplinary teams
FUTURE OF TYPE 1 DIABETES CARE
• AI-supported platforms that analyse CGM data continuously
 • Clinics responding earlier when glucose control deteriorates
 • Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA)
 • More flexible care models where stable patients may need fewer clinic visits
Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00
The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.
Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.
The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2
Enquiries
Collaboration: John Pemberton — [email protected]
Creatives: Anjanee Kohli — [email protected]
Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
X: https://twitter.com/GlucoseNLies
Disclaimer
This content is for informational purposes only and does not constitute medical advice.
© The Glucose Never Lies Ltd. All rights reserved.